Loomis Sayles & Co. L P Decreases Stake in Embecta Corp. $EMBC

Loomis Sayles & Co. L P cut its stake in shares of Embecta Corp. (NASDAQ:EMBC) by 48.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 218,414 shares of the company’s stock after selling 202,816 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Embecta were worth $2,116,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EMBC. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Embecta by 7.9% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock worth $145,000 after buying an additional 1,093 shares during the period. CWM LLC boosted its stake in shares of Embecta by 16.0% during the 2nd quarter. CWM LLC now owns 8,080 shares of the company’s stock worth $78,000 after acquiring an additional 1,115 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Embecta by 2.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after acquiring an additional 1,159 shares during the period. SummerHaven Investment Management LLC increased its stake in Embecta by 1.9% in the 2nd quarter. SummerHaven Investment Management LLC now owns 66,313 shares of the company’s stock valued at $643,000 after purchasing an additional 1,268 shares in the last quarter. Finally, Laurel Wealth Advisors LLC increased its stake in Embecta by 754.3% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,871 shares of the company’s stock valued at $193,000 after purchasing an additional 1,652 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Stock Performance

Shares of EMBC opened at $12.26 on Tuesday. Embecta Corp. has a 1 year low of $9.20 and a 1 year high of $21.48. The company’s 50 day simple moving average is $13.87 and its 200 day simple moving average is $12.50. The company has a market capitalization of $717.04 million, a price-to-earnings ratio of 7.52 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Tuesday, November 25th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.04. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The company had revenue of $263.30 million during the quarter, compared to the consensus estimate of $265.66 million. During the same period in the previous year, the firm posted $0.45 EPS. Embecta’s revenue was down 7.7% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts expect that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Friday, December 5th will be given a dividend of $0.15 per share. The ex-dividend date is Friday, December 5th. This represents a $0.60 annualized dividend and a yield of 4.9%. Embecta’s dividend payout ratio is 36.81%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. BTIG Research reiterated a “buy” rating on shares of Embecta in a research report on Tuesday, November 25th. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “buy” rating in a research report on Friday. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $18.50.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.